natgillin/translations-raw huggingface dataset:
Date of first authorisation: 17/12/2010 Date of last renewal: 08/09/2015 
Datum zadnjega podaljšanja dovoljenja za promet: 08/09/2015
The type of strain(s) (two strains at most) included in the final product will be selected based on the epidemiological situation at the time of manufacturing and will be stated on the label. 
Tip seva (največ dva seva) vključen v končno zdravilo, bo izbran glede na epidemiološko situacijo ob času proizvodnje cepiva in bo naveden na ovojnini.
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini, po EXP.
The duration of immunity for cattle and sheep is 1 year after primary vaccination course. 
Trajanje imunosti: pri govedu in ovcah 1 leto po osnovnem cepljenju.
No other adverse reactions except those mentioned in section 4.6 were observed. 
Drugi neželeni učinki, razen tistih, ki so navedeni v poglavju 4.6, niso bili opaženi.
Appearance: homogeneous milky white. 
Videz: homogen mlečno bel.
For viral culture, inactivation and concentration steps only: MERIAL 
Samo za postopke kultivacije virusa, inaktivacije in koncentracije: MERIAL
Avoid multiple vial broaching. 
Izogibajte se večkratnemu prebadanju stekleničke.
If used in other domestic and wild ruminant species that are considered at risk of infection, its use in these species should be undertaken with care and it is advisable to test the vaccine on a small number of animals prior to mass vaccination. 
Ob uporabi cepiva pri drugih domačih in divjih vrstah prežvekovalcev, ki jih ogroža okužba, je potrebna previdnost; priporočljivo je testno cepljenje manjšega števila živali pred masovnim cepljenjem.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. 
Ni podatkov o varnosti ter učinkovitosti tega cepiva s katerim koli drugim zdravilom za uporabo v veterinarski medicini.
- Second injection: after 3-4 weeks. 
- Drugi odmerek: po 3-4 tednih.
Store and transport refrigerated (2 ºC - 8 ºC). 
Shranjujte in prevažajte v hladilniku (2C - 8C).
Pregnancy and lactation: Can be used during pregnancy and lactation. 
Brejost in laktacija: Lahko se uporablja v obdobju brejosti in laktacije.
Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 69800 Saint-Priest France 
Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 69800 Saint-Priest Francija
(**) Antigen content (VP2 protein) by immuno-assay 
(**) Vsebnost antigena (VP2 protein) z imunološkimi metodami
Incompatibilities: Do not mix with any other veterinary medicinal product. 
Inkompatibilnosti: Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini.
The safety and the efficacy of the vaccine have not been established in breeding males. 
Varnost in učinkovitost cepiva nista bili ugotovljeni pri plemenjakih.
No other adverse reactions except those mentioned in section ‘Adverse Reactions' were observed. 
Drugi neželeni učinki, razen tistih, ki so navedeni v poglavju ‘Neželeni učinki', niso bili opaženi.
Sheep and cattle. 
Ovce in govedo.
2.7 mg 
2,7 mg saponin
*below the level of detection by the validated RT-PCR method at 3.68 log10 RNA copies/ml, indicating no infectious virus transmission 
*pod stopnjo detekcije z validirano metodo RT-PCR pri 3,68 log10 RNA kopijah/ml, ni prenosa virusa
Manufacturer responsible for batch release: MERIAL 
Proizvajalec, odgovoren za sproščanje serij: MERIAL
In very rare cases it has been observed a small local swelling at the injection site (at most 32 cm² in cattle and 24 cm² in sheep) which becomes residual 35 days later (≤ 1 cm In very rare cases a transient increase in body temperature, normally not exceeding an average of 1.1 ºC, may occur within 24 hours after vaccination. 
V zelo redkih primerih se po cepljenju lahko na mestu dajanja pojavi manjša lokalizirana oteklina (največ 32 cm pri govedu in 24 cm pri ovcah), ki postane rezidualna 35 dni pozneje (≤ 1 cm V zelo redkih primerih se lahko v 24 urah po cepljenju pojavi prehodno povišanje telesne temperature, ki navadno ne preseže povprečja 1,1°C .
In this category of animals the vaccine should be used only according to the benefit/risk assessment by the responsible veterinarian and/ or national Competent Authorities on the current vaccination policies against Bluetongue Virus (BTV). 
Pri tej kategoriji živali je potrebno cepivo uporabljati glede na presojo razmerja korist/tveganje odgovornega veterinarja oziroma v skladu z veljavnimi smernicami pristojnih nacionalnih organov glede cepljenja proti bolezni modrikastega jezika (BT).
Sheep and cattle 
Ovce in govedo
The vaccine contains inactivated Bluetongue Virus with aluminium hydroxide and saponin adjuvants. 
Cepivo vsebuje inaktiviran virus bolezni modrikastega jezika z aluminijevim hidroksidom in saponini kot adjuvansoma.
A confirmatory final potency test by seroneutralisation in rats is conducted when a batch is released. 
Končni potrditveni test jakosti je seronevtralizacijski test pri podganah ob sprostitvi serije.
Haemolytic units 
Hemolizne enote
Bottle of 10 and 50 ml 
Steklenička z 10 in 50 ml
Avoid bubble formation, as this can be irritating at the site of injection. 
Izogibajte se nastanku zračnih mehurčkov saj le-ti lahko povzročijo draženje na mestu dajanja.
EXP {month/year} Once broached, use immediately. 
EXP {mesec/leto} Odprto zdravilo uporabite takoj.
For purification and bottling steps only: MERIAL Laboratory of Lyon Porte des Alpes Rue de l'Aviation, 
Samo za postopke purifikacije in polnjenja: MERIAL Laboratory of Lyon Porte des Alpes Rue de l'Aviation,
Silicon antifoam Phosphate buffer Glycine buffer Aluminium hydroxide Saponin 
6.1 Seznam pomožnih snovi silikon (proti penjenju) fosfatni pufer glicerinski pufer aluminijev hidroksid saponin
The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required. 
SPC, so bodisi dovoljene snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št.37/2010 določa, da MRL ni potreben ali pa ne spadajo v področje uporabe Uredbe (ES) št. 470/2009, kadar so uporabljene tako kot v tem zdravilu za uporabo v veterinarski medicini.
Pharmacotherapeutic group: bluetongue virus vaccine, ATC vet code QI04AA02 (sheep) and QI02AA08 (cattle). 
Oznaka ATC vet: QI04AA02 (ovce) in QI02AA08 (govedo).
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Jih ni.
nd injection: after 3-4 weeks 
- Drugi odmerek: po 3-4 tednih
10 doses (10 ml) 50 doses (50 ml) 
10 odmerkov (10 ml) 50 odmerkov (50 ml)
100 doses (100 ml) 
100 odmerkov (100 ml)
Administer one dose of 1 ml subcutaneously according to the following vaccination scheme: 
Injicirajte 1 ml v podkožje po naslednjem razporedu:
Polypropylene bottle of 50 or 100 ml with butyl elastomer closure. 
50 ali 100 ml polipropilenska plastenka z butil elastomerno zaporko.
Active substance*: 
Zdravilne učinkovine*:
10 doses (10 ml) 50 doses (50 ml) 10 x 50 doses (10 x 50 ml) 100 doses (100 ml) 10 x 100 doses (10 x100 ml) 
10 odmerkov (10 ml) 50 odmerkov (50 ml) 10 x 50 odmerkov (10 x 50 ml) 100 odmerkov (100 ml) 10 x 100 odmerkov (10 x 100 ml)
Very rare and transient apathy can be observed after the administration of a double-dose of the vaccine. 
Zelo redko se lahko po dajanju dvakratnega odmerka cepiva pojavi prehodna apatija.
Type I glass bottle of 10 ml with butyl elastomer closure. 
10 ml steklenička (steklo tipa I) z butil elastomerno zaporko.
BTVPUR suspension for injection for sheep and cattle 
BTVPUR suspenzija za injiciranje za ovce in govedo
The entire content of the bottle should be used immediately after broaching and during the same procedure. 
Takoj po odpiranju porabite celotno vsebino stekleničke.
Inactivated BTV1 ..................................................................................................... ≥ 1.9 log10 pixels Inactivated BTV2 ................................................................................................... ≥ 1.82 log10 pixels Inactivated BTV4 ................................................................................................... ≥ 1.86 log10 pixels Inactivated BTV8 ................................................................................................... ≥ 2.12 log10 pixels (*) maximum of two different inactivated bluetongue virus serotypes. 
Inaktiviran BTV1 ……………………………………………………≥ 1,9 log10 pikslov Inaktiviran BTV2……………………………………………………..≥ 1,82 log10 pikslov Inaktiviran BTV4……………………………………………………..≥ 1,86 log10 pikslov Inaktiviran BTV8……………………………………………………..≥ 2,12 log10 pikslov * največ dva različna inaktivirana serotipa virusa bolezni modrikastega jezika
Each dose of 1 ml contains: 
Vsak odmerek (1 ml) vsebuje :
Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 2 (100 ml, 50 ml and 10 ml bottles) and/or 4 (10 ml bottles): 18 months. 
Rok uporabnosti monovalentne ali bivalentne formulacije cepiva z virusom bolezni modrikastega jezika serotip 2 (100 ml , 50 ml in 10 ml plastenka) ali/in 4 (10 ml plastenka): 18 mesecev.
Shelf life of monovalent or bivalent formulation with Bluetongue Virus serotypes 1, 8 (100 ml, 50 ml and 10 ml bottles) and/or 4 (100 ml and 50 ml bottles): 2 years. 
Rok uporabnosti monovalentne ali bivalentne formulacije cepiva z virusoma bolezni modrikastega jezika serotip 1, 8 (100 ml , 50 ml in 10 ml plastenka) ali/in 4 (100 ml, in 50 ml plastenka): 2 leti.
PACKAGE LEAFLET: BTVPUR suspension for injection for sheep and cattle 
NAVODILO ZA UPORABO BTVPUR suspenzija za injiciranje za ovce in govedo
Each dose of 1 ml contains: Active substances *: 
Vsak odmerek (1 ml) vsebuje: Učinkovina(e)*:
Name and address of the manufacturer responsible for batch release 
Ime in naslov proizvajalca zdravila, odgovornega za sproščanja serij
For a monovalent vaccine containing an inactivated Bluetongue Virus serotypes 2 or 4, or for a bivalent vaccine containing both serotypes 2 and 4 together, one injection is sufficient. 
Pri monovalentem cepivu, ki vsebuje inaktiviran virus bolezni modrikastega jezika, serotip 2 ali 4, ali pri bivalentnem cepivu, ki vsebuje oba serotipa 2 in 4 skupaj, zadostuje en odmerek.
For a monovalent vaccine containing an inactivated Bluetongue Virus serotype 2 or 4, or for a bivalent vaccine containing both serotypes 2 and 4 together, one injection is sufficient. 
Pri monovalentnem cepivu, ki vsebuje inaktiviran virus bolezni modrega jezika serotip 2 ali 4, ali bivalentenm cepivu ki vsebuje oba serotipa 2 in 4 skupaj, zadostuje en odmerek.
It induces an active and specific immunity against Bluetongue Virus in the vaccinated animal. 
Pri cepljeni živali sproži nastanek aktivne in specifične imunosti proti virusu bolezni modrikastega jezika.
Box of 1 bottle of 10 doses (1 x 10 ml) 
Škatla z 1 stekleničko z 10 odmerki (1 x 10 ml).
Onset of immunity has been demonstrated 3 weeks (or 5 weeks in sheep for BTV2) after the primary vaccination course for BTV1, BTV2 (cattle), BTV-4 and BTV-8 serotypes. 
Nastop imunosti: 3 tedne po osnovnem cepljenju proti BTV1, BTV2 (govedo), BTV4 in BTV8 serotipe (ali 5 tednov pri ovcah proti BTV2).
1 ml dose*: 
Odmerek (1 ml)*:
Shake gently immediately before use. 
Pred uporabo rahlo pretresite.
Inactivated Bluetongue Virus ......................................... strain specific pass level (log10 pixels) ** * maximum of two different inactivated bluetongue virus serotypes 
Inaktiviran virus modrikastega jezika (BTV) ……………………………… ≥ sev specifični nivo (log10 pikslov)** * največ dva različna inaktivirana serotipa virusa bolezni modrikastega jezika
Inactivated bluetongue virus ........................................ strain specific pass level (log10 pixels) ** (*) maximum of two different inactivated bluetongue virus serotypes 
Inaktiviran virus modrikastega jezika (BTV)……………………………… ≥ sev specifični nivo (log10 pikslov)** * največ dva različna inaktivirana serotipa virusa bolezni modrikastega jezika
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), (če je potrebno) Zelo redko se lahko po dajanju dvakratnega odmerka cepiva pojavi prehodna apatija.
Not all pack sizes may be marketed Box of 1 bottle of 10 doses (1 x 10 ml) Box of 1 bottle of 50 doses (1 x 50 ml) Box of 10 bottles of 50 doses (10 x 50 ml) Box of 1 bottle of 100 doses (1 x 100 ml) Box of 10 bottles of 100 doses (10 x 100 ml) 
PODATKI NA ZUNANJI OVOJNINI Škatla z 1 stekleničko z 10 ml Škatla z 1 plastenko s 50 ml Škatla z 10 plastenkami 50 ml Škatla z 1 plastenko s 100 ml Škatla z 10 plastenkami po 100 ml
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC (PROIZVAJALCI) BIOLOŠKE (BIOLOŠKIH) UČINKOVINE (UČINKOVIN) IN PROIZVAJALEC (PROIZVAJALCI) ZDRAVILA, ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ Ime in naslov proizvajalcev biološke (bioloških) učinkovine (učinkovin)
Saponin 
KARENCA
Active substances *: 
Učinkovina(e)*:
Special precautions for use in animals 
Posebni previdnostni ukrepi za uporabo pri živalih Ni smiselno.
2.12 log10 pixels/mL 
2.12 log10 pikslov/ml
Active immunisation of cattle to prevent viraemia* caused by bluetongue virus serotypes 1, 2, 4 and/or 8, and to reduce clinical signs caused by bluetongue virus serotypes 1, 4 and/or 8 (combination of maximum 2 serotypes). 
Aktivna imunizacija goveda proti virusu bolezni modrikastega jezika, serotip 1, 2, 4 in/ali 8 za preprečitev viremije* in zmanjšanje kliničnih znakov povzročenih s serotipi 1, 4 in/ali 8 (kombinacija največ dveh različnih serotipov).
1.82 log10 pixels/mL 
1.82 log10 pikslov/ml
1.86 log10 pixels/mL 
1.86 log10 pikslov/ml
1.9 log10 pixels/mL 
1.9 log10 pikslov/ml
In cattle: - First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle). 
Govedo - Prvi odmerek: od 1 meseca starosti pri predhodno necepljenih živalih (ali od 2,5 meseca starosti pri mladičih imunih krav).
In sheep: - First injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune sheep). 
Ovce - Prvi odmerek: od 1 meseca starosti pri predhodno necepljenih živalih (ali od 2,5 meseca starosti pri mladičih imunih ovc).
Box of 10 bottles of 100 ml 
Škatla z 10 plastenkami s 100 odmerki (10 x 100 ml).
Box of 1 bottle of 50 ml, 
Škatla z 1 plastenko s 50 odmerki (1 x 50 ml).
In cattle st injection: from 1 month of age in naive animals (or from 2.5 months of age in young animals born to immune cattle). 
Govedo: - Prvi odmerek: od 1 meseca starosti pri predhodno necepljenih živalih (ali od 2,5 meseca starosti pri mladičih imunih krav).
Box of 1 bottle of 100 ml, 
Škatla z 1 plastenko s 100 odmerki (1 x 100 ml).
Box of 10 bottles of 50 ml, 
Škatla z 10 plastenkami s 50 odmerki (10 x 50 ml).
Strength Pharmaceutical Form 
MA (EU) Številka zaščiteno ime jakost farmacevtska oblika pot uporabe Stična ovojnina velikost pakiranja
Pack size 
3 tablete
These may be the signs of an allergic reaction. 
To so lahko znaki alergijske reakcije.
• Adults and elderly 
• Odrasli in starostniki
• Your doctor may order blood tests. 
• lahko vaš zdravnik naroči preiskave krvi.
Hallucinations, confusion 
Halucinacije, zmedenost
Clopidogrel has been evaluated for safety for 1 year or more. 
Varnost klopidogrela so vrednotili v obdobju 1 leta ali več.
MARKETING AUTHORISATION NUMBER(S) EU/1/09/549/001-007 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/09/549/001-007
The application is based on a reference medicinal product for which no safety concerns requiring additional risk minimisation activities have been identified. 
Vloga temelji na referenčnem zdravilu, za katerega niso bila ugotovljena varnostna vprašanja, ki bi zahtevala dodatne aktivnosti za zmanjšanje tveganja.
Neutropenia, including severe neutropenia 
Nevtropenija, vključno s hudo nevtropenijo
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs. 
Vendar pa je zaradi pomanjkanja študij o interakcijah z drugimi NSAIDs danes nejasno, ali je povečano tveganje za gastrointestinalne krvavitve pri vseh NSAIDs.
Do not take a double dose to make up for the forgotten individual doses. 
Ne jemljite dvojnega odmerka, da bi nadomestili posamezne izpuščene odmerke.
• You should tell your doctor if a surgery (including dental) is planned. 
• morate povedati zdravniku, če imate predvideno kakšno operacijo (vključno z zobozdravstvenim posegom).
TTP is a potentially fatal condition requiring prompt treatment including plasmapheresis. 
TTP je potencialno smrtno stanje, ki zahteva takojšnje zdravljenje vključno s plazmaferezo.
Since the CAPRIE trial was not powered to evaluate efficacy of individual subgroups, it is not clear whether the differences in relative risk reduction across qualifying conditions are real, or a result of chance. 
Ker CAPRIE nima moči za oceno učinkovitosti v posameznih podskupinah, ni jasno, ali so razlike pri zmanjšanju relativnega tveganja glede na vključitvene pogoje resnične ali slučajne.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
Študije na živalih ne kažejo neposrednih ali posrednih škodljivih vplivov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj (glejte poglavje 5.3).
83714 Miesbach Germany 
83714 Miesbach Nemčija
In the myocardial infarction subgroup, most of the patients received ASA for the first few days following the acute myocardial infarction. 
V podskupini z miokardnim infarktom je večina bolnikov prejemala ASA prvih nekaj dni po akutnem miokardnem infarktu.
Analysis of total mortality as a secondary endpoint did not show any significant difference between clopidogrel (5.8%) and ASA (6.0%). 
Analiza skupne umrljivosti kot sekundarnega opazovanega dogodka ni pokazala pomembne razlike med klopidogrelom (5,8 %) in ASA (6,0 %).
The MAH must ensure that the system of pharmacovigilance, presented in Module 1.8.1. of the Marketing Authorisation, is in place and functioning before and whilst the product is on the market. 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da je sistem farmakovigilance, predstavljen v modulu 1.8.1 pridobitve dovoljenja za promet z zdravilom, vzpostavljen in deluje, preden da zdravilo v promet in toliko časa, kolikor bo zdravilo v prometu.
Patients should inform physicians and dentists that they are taking clopidogrel before any surgery is scheduled and before any new medicinal product is taken. 
Bolniki morajo obvestiti zdravnika in zobozdravnika, da jemljejo klopidogrel, pred vsakim načrtovanjem kirurškega posega in preden vzamejo katerokoli novo zdravilo.
Their frequency is defined using the following conventions: common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000). 
Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000).
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure. 
O trombotični trombocitopenični purpuri (TTP) so poročali zelo redko po uporabi klopidogrela, včasih po kratki izpostavljenosti.
In addition, your doctor may identify changes in your blood or urine test results. 
Poleg tega lahko zdravnik ugotovi spremenjene izvide preiskav krvi ali urina.
Children and adolescents Clopidogrel Acino Pharma is not intended for use in children or adolescents. 
Otroci in mladostniki Zdravilo Klopidogrel Acino Pharma ni namenjeno za uporabo pri otrocih ali mladostnikih.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu/ 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila : http://www.ema.europa.eu/.
If a patient is to undergo elective surgery and antiplatelet effect is temporarily not desirable, clopidogrel should be discontinued 7 days prior to surgery. 
Če ima bolnik predviden kirurški poseg in antitrombotični učinek začasno ni zaželen, moramo klopidogrel ukiniti 7 dni pred kirurškim posegom.
Acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever: An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor. 
Acetilsalicilna kislina, učinkovina, ki je prisotna v številnih zdravilih, ki se uporabljajo za lajšanje bolečine in zniževanje zvišane telesne temperature: Priložnostna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v kateremkoli 24 urnem obdobju) na splošno ne bi smela povzročati težav, vendar pa se morate o daljši uporabi v drugih okoliščinah posvetovati s svojim zdravnikom.
In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke. 
Zaradi pomanjkanja podatkov klopidogrela ne moremo priporočiti prvih 7 dni po akutni ishemični kapi.
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel, and that they should report any unusual bleeding (site or duration) to their physician. 
Bolniki morajo biti obveščeni, da je lahko čas, potreben za zaustavitev krvavitve, daljši kot ponavadi, ko jemljejo klopidogrel in da morajo poročati svojemu zdravniku o kakršnikoli neobičajni krvavitvi (mesto ali trajanje).
Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued. 
Agregacija trombocitov in čas krvavitve sta se postopoma vrnila na izhodiščno vrednost, na splošno v 5 dneh po ukinitvi zdravljenja.
Patients should be followed carefully for any signs of bleeding including occult bleeding,especially during the first weeks of treatment and/or after invasive cardiac procedures or surgery. 
Bolnike morate skrbno spremljati zaradi znakov krvavitve, vključno z okultno krvavitvijo, zlasti prve tedne zdravljenja in/ali po invazivnih kardioloških postopkih ali kirurških posegih.
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites. 
Absorpcija je najmanj 50 %, na podlagi metabolitov klopidrogela, izločenih z urinom.
In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients ≤75 years. 
Razen tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih ≤ 75 let.
If you forget for more than 12 hours, simply take the next single dose at the usual time. 
Če pozabite za več kot 12 ur, preprosto vzemite naslednji enkratni odmerek ob ustaljenem času.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: 
Klopidogrel je indiciran pri odraslih za preprečevanje aterotrombotičnih dogodkov pri:
If you cut or injure yourself, it may take longer than usual for bleeding to stop. 
Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se vam krvavitev ustavi.
Some other medicines may influence the use of Clopidogrel Acino Pharma or vice versa. 
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Klopidogrel Acino Pharma in obratno.
Clopidogrel should be given as a single daily dose of 75 mg. 
Klopidogrel se mora dajati kot enkratni dnevni odmerek 75 mg.
However, concomitant administration of 500 mg of ASA twice a day for one day did not significantly increase the prolongation of bleeding time induced by clopidogrel intake. 
Vendar pa sočasna uporaba 500 mg ASA dvakrat dnevno en dan ni pomembno povečala podaljšanja časa krvavitve, sprožene z jemanjem klopidogrela.